LPCN
$1.06
Lipocine
($.03)
(2.75%)
LPCN
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.05)
Revenue:  $0.00 Mil
Tuesday
Nov 9
8:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when LPCN reports earnings?
Beat
Meet
Miss

Where is LPCN's stock price going from here?
Up
Flat
Down
Stock chart of LPCN
Analysts
Summary of analysts' recommendations for LPCN
Score
Grade
Pivots
Resistance
$1.12
$1.11
$1.08

$1.07

Support
$1.04
$1.03
$1.00
Tweet
Growth
Description
Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men's and women's health. The Company's lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, indicated for the prevention of preterm birth and is currently in Phase 1. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbInterCeptMerck & Co.Eli LillyZoetisPfizer